



Date: December 15, 2025

To,

The Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G  
Bandra Kurla Complex  
Bandra East  
Mumbai - 400 051

**Symbol: ZOTA**

Dear Sir/Madam,

**Re: Qualified institutions placement (“QIP” or “Issue”) of equity shares of face value of ₹ 10 each (the “Equity Shares”) by Zota Health Care Limited (the “Company”) to qualified institutional buyers (“QIBs”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013, as amended (“Companies Act”), including the rules made thereunder**

**Sub: Outcome of the meeting of the Fund-Raising Committee**

We wish to inform you that pursuant to the approval of the Board at its meeting held on September 4, 2025, and approval of the shareholders of the Company by way of a special resolution passed on September 29, 2025, the Fund-Raising Committee, in its meeting held today i.e. December 15, 2025 has *inter alia* considered and approved the following:

- (i) approval and adoption of the preliminary placement document dated December 15, 2025, and the draft of application form, in connection with the QIP;
- (ii) authorizing the opening of the proposed issue of such number of Equity Shares to eligible qualified institutional buyers through a qualified institutions placement under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) and Section 42 and Section 62 of the Companies Act, 2013, read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, each as amended (the “QIP”) today, i.e. on December 15, 2025; and
- (iii) approved the floor price for the QIP as prescribed under SEBI ICDR Regulations.

We further wish to inform you that the ‘Relevant Date’ for the purpose of the QIP, in terms of the SEBI ICDR Regulations is December 15, 2025, and accordingly the floor price in respect of the QIP, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations is ₹1,615.28 per Equity Share. Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, the Company may, at its discretion, offer a discount of not more than 5% (five percent) on the floor price so calculated for the QIP.

The Fund Raising Committee meeting commenced at 10:10 p.m. and the meeting was concluded at 10:30 p.m.

In relation to the QIP, we are filing the preliminary placement document dated December 15, 2025 with your office. Copy of this intimation is also being made available on the website of the Company at <https://www.zotahealthcare.com/qip/>.

Further, as per Company’s Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (“Code”), the trading window for dealing in the securities of the Company is closed from December 15, 2025 till 48 hours after determination of issue price for all ‘Designated Persons’ as defined in the Code.

We request you to take the above on record pursuant to compliance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

**Thanking you,**

**Yours faithfully**

**For Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
**Place: Surat**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)  
CIN: L24231GJ2000PLC038352